SAN CARLOS, Calif. — January 20, 2026 — Leads & Copy — Natera, Inc. announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026.
EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera’s proprietary, ultra-sensitive LinkedSNP™ technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions.
As previously announced, EXPAND validated Fetal Focus’ ability to identify a broad range of clinically relevant inherited conditions with high accuracy. The oral presentation will detail the study’s key results, along with its robust design, including confirmation of all outcomes against genetic truth.
In addition to EXPAND, Natera and its collaborators will deliver a second oral presentation at SMFM highlighting data from VANISH, a prospective clinical trial which validates the unique ability of Panorama™ NIPT to interpret cell-free DNA patterns in vanishing twin pregnancies.
The full list of Natera presentations at SMFM includes:
February 11, 8:45 AM PT | Presentation # 4 (Oral Plenary Presentation)
Presenter: Rajeevi Madankumar, M.D.
Performance of a single gene non-invasive prenatal screening test for recessive conditions
February 11, 10:30 AM PT | Presentation # 145 (Poster)
Presenter: Vivienne Souter, M.D.
Carrier Screening as a Pathway to In-Utero Therapy
February 12, 1:00 PM PT | Presentation # 65 (Oral Presentation)
Presenter: Lorraine Dugoff, M.D.
Development and Validation of a SNP-based cfDNA test for vanishing twin pregnancies: The VANISH Trial
February 12, 3:30 PM PT | Presentation # 1092 (Poster)
Presenter: Jeffrey T. Meltzer, M.D.
Identification of maternal Alzheimer’s disease risk after an atypical finding on SNP-based prenatal cfDNA screening
Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women’s health at Natera, said that being selected for a plenary session at SMFM highlights the high quality of the EXPAND data and its role in advancing prenatal screening.
Parmar added that supporting women’s health is central to Natera’s mission, and EXPAND reflects their ongoing commitment to generating high-quality clinical evidence that delivers actionable insights in prenatal care.
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. The company aims to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance.
Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.
Contact: Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women’s health at Natera.
Source: Natera
